Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies, which are expected to move into clinical trials in the next several months, were both developed by Purdue University scientists in Indiana, led by Philip…
New Targeted Therapies May Ease Pulmonary Fibrosis, Studies Find
Even in normal times, holidays can be a huge vector for illness. Viruses that thrive during the colder months, such as influenza, can cause serious problems for those with compromised immune systems or poor pulmonary function. This year, with the novel coronavirus, the…
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, has granted $920,000 to a team of researchers at the University at Buffalo (UB) to develop a model that mimics human lung tissue. The researchers say their model should offer an accurate and rapid…
Learning to use supplemental oxygen as a young adult was arguably the hardest part of my idiopathic pulmonary fibrosis (IPF) diagnosis. My life changed once I required the help of a plastic tube with two prongs up my nose to complete basic tasks that most people take for…
Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of therapy, a small study found. …
Bridge Biotherapeutics and Boehringer Ingelheim ended a collaboration and license agreement to develop BBT-877, a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. The companies entered into an agreement in July 2019 and, although no details were provided about its termination, the…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…
Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. While…
I have never met a cohort of people more resilient than children. I am reminded of this every day in my career, as I am privileged to walk alongside families facing hardships and discuss with parents and caregivers how to help their children through difficult times. As a trained therapist,…
A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering this study…
